Literature DB >> 27907817

Moderators of change in an Internet-based intervention for eating disorders with different levels of therapist support: What works for whom?

Jiska J Aardoom1, Alexandra E Dingemans2, Marjolein Fokkema3, Philip Spinhoven4, Eric F Van Furth5.   

Abstract

This study investigated moderators of intervention response in a fully automated Internet-based monitoring and feedback intervention ('Featback') with different levels of therapist support for individuals with eating disorder (ED) symptoms. This study was part of a randomized controlled trial comparing four conditions: 1) Featback, 2) Featback with low-intensity (weekly) therapist support, 3) Featback with high-intensity (three times a week) therapist support, and 4) a waiting list. A total of 273 participants completed baseline and post-intervention assessments. The outcome measure was ED psychopathology. Model-based recursive partitioning was applied. Baseline levels of ED psychopathology were found to moderate intervention response. Specifically, in terms of improvement in symptoms of anorexia nervosa, participants with higher baseline levels of anorectic psychopathology showed better outcomes in the waiting list condition and the Featback conditions with low- and high-intensity therapist support in comparison with Featback without therapist support. In terms of improvement in symptoms of bulimia nervosa, participants with mild to moderate bulimic symptoms had better outcomes in the Featback conditions compared with the waiting list. Thus, the fully automated Internet-based intervention with and without therapist support may be particularly suitable in improving mild to moderate bulimic psychopathology, whereas the intervention without therapist support may be less effective in improving severe anorectic psychopathology. Further investigating differential intervention responses is important, as this could help to optimize the delivery and dissemination of E-health interventions and therapist support, which in turn could help moving toward personalized (E-)care.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anorexia nervosa; Bulimia nervosa; E-Health; Eating disorders; Internet-based; Moderators; Therapist support

Mesh:

Year:  2016        PMID: 27907817     DOI: 10.1016/j.brat.2016.11.012

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  4 in total

1.  The COVID-19 pandemic and eating disorders in children, adolescents, and emerging adults: virtual care recommendations from the Canadian consensus panel during COVID-19 and beyond.

Authors:  Jennifer Couturier; Danielle Pellegrini; Catherine Miller; Neera Bhatnagar; Ahmed Boachie; Kerry Bourret; Melissa Brouwers; Jennifer S Coelho; Gina Dimitropoulos; Sheri Findlay; Catherine Ford; Josie Geller; Seena Grewal; Joanne Gusella; Leanna Isserlin; Monique Jericho; Natasha Johnson; Debra K Katzman; Melissa Kimber; Adele Lafrance; Anick Leclerc; Rachel Loewen; Techiya Loewen; Gail McVey; Mark Norris; David Pilon; Wendy Preskow; Wendy Spettigue; Cathleen Steinegger; Elizabeth Waite; Cheryl Webb
Journal:  J Eat Disord       Date:  2021-04-16

2.  A reliability and content analysis of Italian language anorexia nervosa-related websites.

Authors:  Nicola Luigi Bragazzi; Giulia Prasso; Tania Simona Re; Riccardo Zerbetto; Giovanni Del Puente
Journal:  Risk Manag Healthc Policy       Date:  2019-08-01

Review 3.  Review of Randomized Controlled Trials Using e-Health Interventions for Patients With Eating Disorders.

Authors:  Mojtaba Ahmadiankalati; Sabine Steins-Loeber; Georgios Paslakis
Journal:  Front Psychiatry       Date:  2020-06-12       Impact factor: 4.157

4.  A randomized controlled trial of an Internet-based intervention for eating disorders and the added value of expert-patient support: study protocol.

Authors:  Pieter J Rohrbach; Alexandra E Dingemans; Philip Spinhoven; Elske Van den Akker-Van Marle; Joost R Van Ginkel; Marjolein Fokkema; Markus Moessner; Stephanie Bauer; Eric F Van Furth
Journal:  Trials       Date:  2019-08-16       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.